revenue $2.3M, net income -$69.4M. Wave Life Sciences Q2 loss widens 40% as revenue falls 73.9%; GSK AATD termination boosts H1 revenue

Filed July 30, 2026 · Period ending June 30, 2026 · Compared to 10-Q Jul 30, 2025 · ~1 min read

Key Changes

• high

  Q2 operating loss widened, driven by higher R&D and G&A expenses, while total revenue fell 73.9% to $2.3M.

  MD&A: Operating Results verify on EDGAR →
• high

  Six-month revenue jumped from due to an one-time deferred revenue recognition from terminating the GSK AATD license.

  MD&A: Revenue verify on EDGAR →
• high

  Cash and marketable securities totaled at June 30, 2026, providing runway into 2028.

  MD&A: Liquidity verify on EDGAR →